Hormonal
Once-weekly subcutaneous semaglutide at 2.4mg induces significant weight loss (mean 14.9%) in adults with obesity, significantly outperforming placebo.
For adults with obesity, once-weekly subcutaneous semaglutide at 2.4mg is a highly effective treatment for weight loss, averaging a 14.9% reduction in body weight over 68 weeks when combined with lifestyle changes. This is significantly better than placebo. Patients should expect potential gastrointestinal side effects, which are usually temporary, and adhere to the titration schedule to minimize them.
Semaglutide-treated subjects achieved a mean weight loss of 14.9%, (from baseline body weight of 105.3 kg) compared to a 2.4% weight loss with placebo; 86.4% achieved weight loss > 5% compared to 31.5% with placebo.
Why this rating
Based on Phase 3 RCT (STEP 1) with 1,961 participants, meeting co-primary endpoints with high statistical significance.
Source
Recent developments in <scp>GLP‐1RA</scp> therapy: A review of the latest evidence of efficacy and safety and differences within the class
Evie Bain et al. · Diabetes Obesity and Metabolism · 2021
DOI 10.1111/dom.14487
More from this paper
- Once-weekly subcutaneous semaglutide at 1.0mg significantly lowers HbA1c and promotes weight loss in patients with Type 2 Diabetes compared to other glucose-lowering therapies.Strong
- Once-weekly subcutaneous semaglutide at 2.4mg reduces the risk of major adverse cardiovascular events (MACE) in overweight or obese individuals with cardiovascular disease who do not have diabetes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →